42 results about "Insulin response" patented technology

Methods are provided for reducing serum proinsulin levels, lessening post-prandial pancreatic stress, and reducing risk factors for atherosclerosis in subjects with diabetes mellitus, type 2. The method includes administration of insulin in a manner that mimics the meal-related first phase insulin response, using a dose sufficient to reduce serum levels of proinsulin. In some embodiments of the method insulin administration is commenced early in the course of the disease. Mimicking first phase kinetics, peak serum insulin levels can be reached within about 18 minutes of administration. In increasingly preferred embodiments peak serum insulin levels can be reached within about 15, 12, or 10 minutes of administration. Serum insulin levels return to baseline within about two hours of administration.

Disclosed are methods, compositions, and cells useful for increasing insulin sensitivity, as well as lack of insulin production in a host in need thereof. One aspect of the invention discloses methods of increasing skeletal muscle perfusion through administration of cells capable of directly and/or indirectly stimulatory of angiogenesis and/or vascular responsiveness. Another aspect provides means of increasing sensitivity to insulin through administration of a cell composition capable of integrating into host insulin responsive tissue and upregulating responsiveness either through mobilization of host cells capable of responding to insulin, mobilization of host cells capable of endowing insulin responsiveness on other host cells, exogenously administered cells taking the role of insulin responsiveness, or exogenously administered cells endowing insulin responsiveness on other host cells. Another aspect comprises modifying said host to allow for concurrent insulin sensitization and upregulated production of insulin.

A controller for an artificial pancreas for automated insulin delivery to patients with type 1 diabetes mellitus (T1DM) that enforces safe insulin delivery throughout both day and night, wherein the controller employs zone model predictive control, whereby real-time optimization, based on a model of a human's insulin response, is utilized to regulate blood glucose levels to a safe zone, and time-dependent zones that smoothly modulate the controller correction based on the time of day, wherein the controller strategically strives to maintain an 80-140 mg/dL glucose zone during the day, a 110-220 mg/dL zone at night, and a smooth transition of 2 hour duration in between.

A therapeutic agent and prophylactic agent for a disease accompanying an abnormality in an amount of insulin or insulin response, an agent for an insulin-mimetic action, a food, beverage and feed, an agent for enhancing glucose uptake into a cell, and an agent for inducing differentiation into an adipocyte, characterized in that each comprises as an effective ingredient at least one compound selected from the group consisting of a chalcone compound, an acetophenone compound, a coumarin compound, a phthalide compound, derivatives thereof, and pharmacologically acceptable salts thereof.

A drug delivery device (100) for administering a low dose of a medicament includes a housing (111) and a drug reservoir (101) disposed in the housing (111). A needle (135) is connected to the drug reservoir (101). A pressure applying member (113) is movably connected to the housing (111) and is movable between first and second positions. The pressure applying member (113) does not apply pressure to the drug reservoir (101) in the first position and applies pressure to the drug reservoir (101) in the second position to dispense medicament stored in the drug reservoir (101). A method of administering a low dose of insulin to simulate a first-phase insulin response of a pancreas is also disclosed.

The object of the present invention is to provide a method of preparing excellent cultured muscle cells having high metabolic capacity and insulin responsiveness, and further provide a method for the measurement of sensitive metabolic capacity using the cells. Moreover, its purpose is to provide a culture system/culture apparatus that can smoothly translocate such highly advanced cultured muscle cells intact to activity evaluation systems of a number of drugs. Moreover, the object of the present invention is to provide cultured muscle cells that are very suitable for measurement of the membrane-translocation activity of GLUT4 in an extraneous stimulus-dependent manner such as insulin, etc., and to provide a method for the measurement of the membrane-translocation activity of GLUT4 using the cells. The present invention is a method of preparing myotube cells, comprising a step (1) of culturing myoblast cells, a step (2) of differentiation-inducing the myotube cells into the myoblast cells in a culture medium with a high content of amino acids, and a step (3) of applying an electric pulse to the differentiation-induced myotube cells, and a method for the measurement of insulin-dependent sugar uptake using the myotube cells prepared by said method, and relates to the method for the measurement, comprising applying insulin stimulation by culturing the cells in a culture medium containing insulin, culturing the cells in the culture medium further supplemented with sugar, and measuring the sugar uptake. Furthermore, the present invention relates to a differentiation-type culture myotube cell constitutively expressing a recombinant GLUT4 having a labeled substance at its extra-cellular site, which is prepared by co-culturing wild-type myoblast cells and recombinant myoblast cells constitutively expressing said recombinant GLUT4, and a method for the measurement of membrane-translocation activity of the recombinant GLUT4 using the cells, and particularly a method for the measurement of insulin-dependent sugar uptake activity.

Co-products from juice extraction, in particular for use in beverage and food products to enhance the metabolic and gut health benefits, including an enhanced feeling of satiety, a reduction of postprandial glucose response, reduction of postprandial insulin response, an increased fermentability by colonic microlfora, an increase short-chain fatty acid production in the colon provided to the consumer are provided. The co-product has a number average particle size of between 1 and 2000 microns, a total polyphenol content of at least 2500 parts per million, a moisture content of between 70% and 85% by weight, and a combined peel and seed content between 0.01% and 20% by weight.

A therapeutic agent and prophylactic agent for a disease accompanying an abnormality in an amount of insulin or insulin response, an agent for an insulin-mimetic action, a food, beverage and feed, an agent for enhancing glucose uptake into a cell, and an agent for inducing differentiation into an adipocyte, characterized in that each comprises as an effective ingredient at least one compound selected from the group consisting of a chalcone compound, an acetophenone compound, a coumarin compound, a phthalide compound, derivatives thereof, and pharmacologically acceptable salts thereof.

Co-products from juice extraction, in particular for use in beverage and food products to enhance the metabolic and gut health benefits, including an enhanced feeling of satiety, a reduction of postprandial glucose response, reduction of postprandial insulin response, an increased fermentability by colonic microflora, an increase short-chain fatty acid production in the colon provided to the consumer are provided. The co-product has a number average particle size of between 1 and 2000 microns, a peel and seed content between 0.01% and 80% by weight, and dietary fiber.

The present invention relates to a therapeutic agent and prophylactic agent for a disease accompanying an abnormality in an amount of insulin or insulin response, an agent for an insulin-mimetic action, a food, beverage and feed for treating a preventing a disease accompanying an abnormality in an amount of insulin or insulin response, an agent for enhancing glucose uptake into a cell, and an agent for inducing differentiation into an adipocyte, characterized in that each comprises as an effective ingredient a processed product derived from at least one plant selected from the group consisting of (a) a plant belonging to Tiliaceae, (b) a plant belonging to Zingiberaceae, (c) a plant belonging to Compositae, (d) a plant belonging to Liliaceae, and (e) a plant belonging to Polygonaceae.

The invention relates to extracts produced from sugar cane processing stream products having desirable properties and health benefits. More particularly the invention relates to sugar cane derived extracts obtained from molasses, methods of producing the extracts, and uses of the extracts for management of insulin resistant conditions or subjects predisposed to such conditions, such as type 2 diabetes. The sugar cane derived extracts of the invention are enriched in polyphenols and the administration of the sugar cane derived extract regulates postprandial glucose response and insulin response and lowering those responses, to avoid the subject becoming hypoglycaemic.

The invention relates to the field of physiological signal processing, and provides an insulin recommendation method and device and a blood glucose level monitoring system. The method comprises the steps of conducting regularization on key feature data of a user, to obtain at least two matched feature values; performing matching in a case library based on the at least two matching feature values; if the matching succeeds, selecting a first insulin recommendation scheme based on the ranking of the scores; if the matching fails, outputting a second insulin recommendation scheme; updating the case library based on feedback information of the user for the recommendation, wherein when the user accepts the recommendation, the feedback information comprises a first insulin recommendation scheme and a score thereof or a second insulin recommendation scheme and a score thereof, when the user does not accept the recommendation, the feedback information comprises the insulin response scheme adopted by the user and the score of the insulin response scheme, and the score is determined based on the target blood glucose time proportion and/or the blood glucose concentration change rate of the second time period. According to the invention, a user can enjoy richer and more reasonable recommendation, and the user experience is improved.

Co-products from juice extraction, in particular for use in beverage and food products to enhance the metabolic and gut health benefits, including an enhanced feeling of satiety, a reduction of postprandial glucose response, reduction of postprandial insulin response, an increased fermentability by colonic microlfora, an increase short-chain fatty acid production in the colon provided to the consumer are provided. The co-product has a number average particle size of between 1 and 2000 microns, a total polyphenol content of at least 2500 parts per million, a moisture content of between 70% and 85% by weight, and a combined peel and seed content between 0.01% and 20% by weight.

The invention discloses a sugar control composition containing quinoa and preparation method thereof. The preparation method comprises the following steps: respectively weighing the following components in percentage by mass: 25-40% of quinoa, 10-20% of purple rice, 10-20% of white kidney beans, 10-20% of oats and 10-20% of walnuts, the sum of the mass percentages of the components being 100%; in the formula, vitamin B1 in the quinoa and coarse cereals in the formula can maintain normal glycometabolism and nerve conduction functions of diabetic patients, and can help diabetic patients to maintain capillary health and avoid microangiopathy; so that the composition is capable of improving the kidney cell metabolism disorder caused by hypertension, wherein magnesium can better help the blood sugar of the diabetic patient to be converted into energy, and meanwhile insulin response is improved. In addition, the n-3 series of polyunsaturated fatty acids in the walnuts can help and enhance cell activity, then increase insulin receptors, make insulin very sensitive, increase blood sugar consumption and convert blood sugar into glycogen.

The present invention discloses a nourishing health care pastry of the Dong Minority. The pastry includes the following components by weight: 15-25 parts of Chinese fevervine herb and root juice, 32-55 parts of glutinous rice, 30-36 Poria cocos, 3-8 parts of soya-bean milk, 3-8 parts of Chinese yam, 3-8 parts of sweet potato, 0.5-2 parts of edible salt, 0.5-2 parts of cooked sesame seeds, 5-8 parts of cactus juice, 12-15 parts of isomalt, 3-5 parts of red wine, 6-8 parts of Radix Astragali, 3-8 parts of Rhizoma Dioscoreae from Henan of China, 8-12 parts of Chinese angelica and 9-12 parts of Arenga pinnata powder. The invention also discloses a preparation technology of the nourishing health care pastry of the Dong Minority. The pastry of the Dong Minority prepared by the unique formula and process is instant, rich in nutrition, and has crispy taste; the a variety of added traditional Chinese medicines taste good; red wine also has the effect of treating cardiovascular and cerebrovascular diseases, and the cactus juice has certain effects of reducing blood sugar, helping weight loss and reducing blood pressure effect; the insulin response produced by isomalt is 12 times less than that of similar products made from sucrose; therefore, the pastry of the Dong Minority is applicable to the patients with dental caries and diabetes.

Bone marrow cells have been demonstrated to be useful in the maintenance of pancreatic islet β cell viability, structure, and/or function in culture for a sustained period. Bone marrow cells were also found to promote β cell growth while reducing inflammatory cytokine release and reduce apoptosis. Moreover, islet cells co-cultured with bone marrow cells were shown to retain insulin response function and to function in an islet cell transplant in a mouse model of diabetes to restore normal insulin secretion. Cord blood cells and isolated peripheral CD34+ blood cells were unable to support β islet cell growth or increase survival.

The invention discloses a preparation method for plant effective nutrient elements. The plant effective nutrient elements are effective nutrient elements reserved in plants after carbohydrate in the natural plants which can be digested and absorbed by human bodies is removed. The preparation flow is that plant fruits are selected and are peeled; solution color protection, pulping, extraction and filtration are conducted to obtain filtrate A; enzymolysis is conducted to solids obtained after extraction; secondary filtration is conducted, the obtained filtrate is discarded, and secondary enzymolysis is conducted to the obtained filtered cake after complex enzyme is added; after enzymolysis, tertiary filtration is conducted to obtain filtrate B; the filtrate B is combined with the filtrate A and the obtained mixed filtrate is lyophilized at low temperature; and screening and packaging are conducted. The content of resistant starch in effective ingredients of the plant effective nutrient elements is more than 80 percent. The plant effective nutrient elements have the efficacies of reducing blood glucose value and insulin response after dinner, relieving diabetes, reducing the pH value in the intestinal tract, preventing colorectal cancers, improving constipation conditions; proliferating beneficial bacteria, inhibiting pernicious bacteria, enhancing lipid metabolism, maintaining cardiovascular health, controlling body weight increase, increasing mineral absorption and the like.

The present invention provides an extract obtained by extracting a plant of the Japanese parsley family or treatment product thereof with an aqueous alcohol; a process for producing the extract; a therapeutic agent or preventive for diabetic complications and/or diseases accompanied by inflection of insulin level or insulin response, characterized by containing the above extract as an active ingredient; an insulin-like acting agent characterized by containing the above extract as an active ingredient; a food, drink or feed characterized by containing the above extract; a promoter of glucose intake in cells characterized by containing the above extract as an active ingredient; a differentiation inducer to fat cells characterized by containing the above extract as an active ingredient; and an aldose reductase inhibitor characterized by containing the above extract as an active ingredient.

The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications associated with insulin response. Specifically, the invention relates to small interfering RNA (siRNA) molecules capable of mediating RNA interference (RNAi) against PTP-1B polypeptide and polynucleotide targets.